BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wesdorp IC, Dekker W, Festen HP. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci. 1993;38:2287-2293. [PMID: 8261835 DOI: 10.1007/bf01299910] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999;44 Suppl 2:S1-16. [PMID: 10741335 DOI: 10.1136/gut.44.2008.s1] [Cited by in Crossref: 545] [Cited by in F6Publishing: 113] [Article Influence: 24.8] [Reference Citation Analysis]
2 Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut 2004;53 Suppl 4:iv58-65. [PMID: 15082617 DOI: 10.1136/gut.2003.034371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
3 Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995;49:695-710. [PMID: 7601011 DOI: 10.2165/00003495-199549050-00005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
4 Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, Wong BC. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005;11:4067-77. [PMID: 15996033 DOI: 10.3748/wjg.v11.i26.4067] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
5 Duru CE, Umar HIU, Duru IA, Enenebeaku UE, Ngozi-Olehi LC, Enyoh CE. Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective. Environ Anal Health Toxicol 2021;36:e2021010-0. [PMID: 34130375 DOI: 10.5620/eaht.2021010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wurm P, De Caestecker J. Emerging drugs for gastro-oesophageal reflux disease. Expert Opin Emerg Drugs 2005;10:457-71. [PMID: 15934879 DOI: 10.1517/14728214.10.2.457] [Reference Citation Analysis]
7 Moayyedi P, Santana J, Khan M, Preston C, Donnellan C; Cochrane Upper GI and Pancreatic Diseases Group. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd003244.pub3] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]